Document is current
Any future updates will be listed below
-
Authors
Schwegel, Nora
Strohhofer, Christoph
Kolesnik, Ewald https://orcid.org/0000-0002-9349-8068
Oltean, Sabrina
Hüttmair, Alexander
Pipp, Christian
Benedikt, Martin
Verheyen, Nicolas
Gollmer, Johannes
Ablasser, Klemens
Wallner, Markus
Santner, Viktoria
Tripolt, Norbert
Pferschy, Peter
Zechner, Peter
Alber, Hannes
Siller-Matula, Jolanta M.
Kopp, Kristen
Zirlik, Andreas
Aziz, Faisal
Sourij, Harald
von Lewinski, Dirk
-
Funding
Funding for this research was provided by:
Medical University of Graz
- License Information
-
More Information
Article History
Received: 3 January 2024
Accepted: 14 August 2024
First Online: 16 September 2024
Declarations
:
: HS is on the advisory board and speakers bureau of Boehringer Ingelheim, NovoNordisk, Sanofi-Aventis, Amgen, AstraZeneca, Bayer, Eli Lilly, Kapsch, MSD, and Daiichi Sankyo. DvL is on the advisory board and speaker’s bureau of by Boehringer Ingelheim, Novartis, Sanova, Sanofi, Orion, AstraZeneca, Bayer Recardio, Vaxxinity and Daiichi Sankyo. NS and EK report no conflict of interest related to this study. All other authors report no conflict of interest related to this study.
: The EMMY trial was approved by the Ethics committee of the Medical University of Graz, Austria (EK 29–179 ex16/17, EudraCT 2016–004591-22) and registered at ClinicalTrials.gov (NCT03087773). The trial conformed to the 1964 Declaration of Helsinki and adhered to the guidelines of Good Clinical Practice (ICH GCP E6). All study participants provided written consent.
: All authors consent for the publication of this study.
